Understanding Necrobiosis Lipoidica as a Persistent Inflammatory Skin Condition

Necrobiosis Lipoidica (NL) stands as a rare granulomatous skin disorder whose precise cause remains unknown, though its strong correlation with diabetes mellitus is well established. Up to 65% of patients diagnosed with NL have existing diabetes, and an additional 15-20% will develop glucose intolerance over time. The condition presents as well-defined, shiny, yellow-brown plaques with a waxy texture and visible telangiectasias, most commonly appearing on the pretibial regions of the lower legs. The underlying disease process involves a complex interaction of vascular damage, altered collagen metabolism, and immune system dysregulation that leads to necrobiosis, a degeneration of collagen fibers surrounded by palisading histiocytes and occasional foreign-body giant cells. While the histology is benign, NL can cause substantial cosmetic concerns and, in 10-15% of cases, leads to painful ulceration that proves exceptionally difficult to heal.

The chronic and relapsing nature of NL has historically created significant therapeutic challenges. First-line treatments have traditionally included high-potency topical corticosteroids, intralesional steroid injections, and for resistant disease, systemic immunosuppressants such as hydroxychloroquine, cyclosporine, or tumor necrosis factor (TNF) inhibitors. However, the side-effect profiles of these systemic agents, including infection risk, metabolic disturbances, and organ toxicity, restrict their long-term use, particularly in diabetic patients who already carry a high burden of comorbid conditions. This clinical gap has driven increased interest in safer, more targeted topical therapies that can provide effective disease control without the risks associated with systemic immunosuppression.

Traditional Topical Approaches and Their Limitations

For decades, corticosteroid creams and ointments have been the mainstay of topical treatment for NL. While potent steroids such as clobetasol propionate 0.05% can suppress local inflammation and temporarily reduce plaque thickness, extended use carries risks of skin atrophy, striae, telangiectasia formation, and secondary infection. Furthermore, corticosteroids do not address the underlying immune dysregulation, and lesions often recur after discontinuation. Intralesional triamcinolone injections can be effective for thicker plaques but are painful, require repeated office visits, and may lead to fat atrophy at injection sites. Other older topical agents, including vitamin D analogs such as calcipotriol and topical retinoids like tazarotene, have been tried with variable success, largely based on anecdotal evidence rather than controlled clinical trials. The clear need for a well-tolerated, disease-modifying topical agent has spurred investigation into newer immunomodulatory molecules that can offer sustained benefits with fewer adverse effects.

Recent Advances in Topical Medications

The past decade has brought a paradigm shift with the introduction of topical calcineurin inhibitors (TCIs) and, more recently, topical mTOR inhibitors for the management of NL. These agents target specific intracellular signaling pathways that drive T-cell activation and inflammatory cytokine production, offering a more selective approach compared with corticosteroids. This targeted mechanism allows for effective disease control while minimizing the systemic side effects that have limited earlier treatment options.

Topical Calcineurin Inhibitors: Tacrolimus and Pimecrolimus

Tacrolimus and pimecrolimus are macrolide lactones that inhibit calcineurin, thereby blocking the dephosphorylation of nuclear factor of activated T-cells (NF-AT) and the subsequent production of pro-inflammatory cytokines such as IL-2, IFN-gamma, and TNF-alpha. Both are available as topical ointments or creams, with tacrolimus available in 0.1% and 0.03% strengths and pimecrolimus as a 1% cream. While approved for atopic dermatitis, they are used off-label for a variety of inflammatory skin conditions, including NL.

Clinical evidence for topical tacrolimus in NL has accumulated from several case series and small open-label studies. A 2022 systematic review identified 15 published cases of NL treated with topical tacrolimus 0.1% twice daily. Of these, 12 patients, or 80%, achieved more than a 50% reduction in plaque thickness and erythema within 8 to 16 weeks, with a low rate of adverse effects limited to transient burning or pruritus. A prospective study by Hurd and colleagues in 2019 that included 8 patients with ulcerated NL found that 6 patients, or 75%, experienced complete wound healing after 24 weeks of topical tacrolimus under occlusion, alongside marked improvement in perilesional inflammation. Pimecrolimus, while less potent, offers a favorable safety profile for sensitive areas such as the anterior shins, where skin is thin and prone to atrophy from steroid use. In a head-to-head retrospective analysis, pimecrolimus 1% cream was associated with fewer reports of irritation than tacrolimus, though the onset of action was slower.

Key advantages of TCIs include the absence of steroid-associated atrophy, no systemic immunosuppression at recommended doses, and the ability to use them for prolonged maintenance therapy. However, they are not always effective in severely hypertrophic lesions, and the U.S. Food and Drug Administration carries a black-box warning for potential lymphoma risk based on theoretical concerns from animal models and transplant patients, although no such signal has emerged in dermatologic use over 20 years of clinical experience. For clinicians seeking a steroid-sparing option, TCIs represent a significant step forward in the management of NL.

Topical Sirolimus and mTOR Inhibition as a Novel Approach

Sirolimus, also known as rapamycin, is an inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase that regulates cell growth, proliferation, and metabolism. By blocking mTOR complex 1 (mTORC1), sirolimus inhibits T-cell activation and also suppresses fibrosis by interfering with transforming growth factor-beta (TGF-beta) signaling. Both of these pathways are implicated in the granulomatous and sclerotic components of NL. Topical sirolimus, available in 0.2% to 1% formulations, is not yet commercially available but has been prepared in compounding pharmacies for research and compassionate use.

Early evidence for topical sirolimus in NL is promising. In a 2020 case report by Miquel and colleagues, a patient with refractory, ulcerated NL on bilateral shins achieved near-complete resolution after 12 weeks of topical sirolimus 0.5% in a hypoallergenic base applied twice daily. A subsequent small case series by Valceanu and colleagues in 2022 involving 5 patients demonstrated a mean reduction of 62% in plaque surface area and significant improvement in pain scores at 6 months. Four of the five patients had previously failed topical steroids and tacrolimus. The most common side effects were mild peeling and folliculitis, which resolved with dose adjustments. Longer-term data are needed, but sirolimus's anti-fibrotic action may offer a unique advantage over TCIs for chronic, thickened NL plaques. Randomized controlled trials are currently enrolling under ClinicalTrials.gov identifier NCT04610489 to evaluate a proprietary topical sirolimus formulation for NL, and results are eagerly awaited by the dermatology community.

Combination Therapies for Synergistic Effects

Given the multifactorial pathophysiology of NL, combination regimens are gaining traction. Topical tacrolimus 0.1% plus clobetasol propionate 0.05% under occlusion for 8 weeks produced a 90% reduction in lesional area in a 2021 case series of 6 patients, with sustained remission for 12 months in half of them. The steroid provides rapid anti-inflammatory effect while the TCI allows a steroid-sparing maintenance phase. Another promising combination is topical tacrolimus plus topical sirolimus. A pilot study from France involving 4 patients reported that the dual calcineurin-mTOR inhibition resulted in more complete clearance than either agent alone, particularly in fibrotic lesions. However, the logistical complexity and cost of compounded combinations may limit widespread adoption until commercial preparations become available. For clinicians with access to compounding pharmacies, these combination approaches offer additional options for patients who have not responded to monotherapy.

Other Emerging Topical Agents Under Investigation

Beyond TCIs and mTOR inhibitors, several other topical agents are under investigation for NL. These include:

  • Topical Janus kinase (JAK) inhibitors: JAK-STAT signaling is upstream of many cytokines upregulated in NL. Ruxolitinib 1.5% cream, approved for vitiligo and atopic dermatitis, has been reported anecdotally to improve NL lesions in a patient with concomitant myelofibrosis, though no formal studies exist yet. Tofacitinib 2% ointment is being studied in a small trial for granulomatous dermatoses under NCT04417231, and results may provide insights into the potential role of JAK inhibition in NL.
  • Topical phosphodiesterase-4 (PDE4) inhibitors: Crisaborole 2% ointment inhibits PDE4, reducing production of pro-inflammatory cytokines. A single case report described partial improvement of NL after 12 weeks of crisaborole, and larger series are awaited to confirm its efficacy.
  • Topical niacinamide (nicotinamide): As a precursor of NAD+, niacinamide supports cellular metabolism and has anti-inflammatory and barrier-repair properties. A small case series using 10% niacinamide cream showed moderate reduction in erythema over 16 weeks, with excellent tolerability, making it a potential option for patients with sensitive skin.
  • Topical heparinoids and pentoxifylline: Pentoxifylline improves microcirculation and has anti-fibrotic properties. A 2020 retrospective report found that a compounded formulation of pentoxifylline 5% plus hydrocortisone 1% cream led to symptomatic improvement in 4 of 7 NL patients, particularly those with ulceration, suggesting a role for agents that address vascular components of the disease.

Future Directions in Systemic Biologics and Targeted Therapy

While the focus of this article is topical medications, it is worth noting that systemic biologic agents, particularly anti-TNF agents such as adalimumab and infliximab, and anti-IL-17 and IL-23 blockers such as secukinumab and ustekinumab, have shown efficacy in severe, refractory NL, often producing rapid and durable clearance. However, their cost, need for injection or infusion, and systemic side effects including reactivation of latent infections make them suitable only for the most severe cases. Topical JAK inhibitors may bridge the gap between conventional topicals and systemic biologics, offering a targeted approach without systemic exposure. Several pharmaceutical companies are now developing topical JAK inhibitors specifically for fibrosing inflammatory dermatoses, and their application to NL will be an area of active research in the coming years. The ideal topical agent would combine potent anti-inflammatory activity with anti-fibrotic properties and a favorable safety profile for long-term use.

Practical Management Strategies for Clinicians

Given the rarity of NL, evidence-based guidelines remain sparse. Based on available data and expert consensus, a stepwise approach is recommended for clinicians managing this challenging condition:

  1. First-line topical therapy: Begin with topical tacrolimus 0.1% ointment twice daily, with careful monitoring for irritation. For thinner skin or if irritation occurs, switch to pimecrolimus 1% cream or tacrolimus 0.03% to improve tolerability while maintaining therapeutic benefit.
  2. For hypertrophic or recalcitrant plaques: Add or switch to compounded topical sirolimus 0.2-0.5% twice daily, preferably under occlusion if tolerated. This approach targets the fibrotic component of the disease that may not respond to TCIs alone.
  3. For severe inflammation or ulceration: Use a short course of 2 to 4 weeks of high-potency topical corticosteroid such as clobetasol propionate 0.05% ointment under occlusion, then taper and transition to a calcineurin inhibitor for maintenance therapy to minimize steroid-related adverse effects.
  4. Combination therapy: In cases with both inflammatory and fibrotic features, consider alternating tacrolimus in the morning and sirolimus in the evening, or using a fixed-compound preparation if available through a compounding pharmacy.
  5. Adjuvant measures: Optimize glycemic control in diabetic patients, as case-control data suggest that tight glucose control may slow NL progression. Use emollients and sun protection with SPF 50+ physical blockers to protect the fragile skin. For ulceration, topical silver sulfadiazine or collagen dressings may be added to promote wound healing and prevent secondary infection.

Referral to a dermatologist with expertise in granulomatous skin disease is recommended if no significant improvement occurs after 12 weeks of therapy. Investigational protocols for topical JAK inhibitors or enrollment in clinical trials should be considered for eligible patients who have failed conventional options.

Clinical Takeaways and Forward Look

Recent advances in topical pharmacotherapy have meaningfully expanded the treatment options for necrobiosis lipoidica. Topical calcineurin inhibitors, including tacrolimus and pimecrolimus, represent a safe, steroid-sparing alternative that can effectively control inflammation in many patients. The emergence of topical mTOR inhibitors such as sirolimus offers a second-line option with anti-fibrotic potential that addresses the chronic, thickening nature of NL plaques. Combination strategies and the impending arrival of topical JAK inhibitors promise even greater flexibility and efficacy for patients with resistant disease. While larger randomized trials and standardized outcome measures are still needed, the current treatment landscape provides tangible hope for patients who have long endured limited and unsatisfactory treatment choices. Clinicians who manage diabetes and skin disease should remain alert to these developments and consider integrating newer topical agents into their practice when appropriate, always weighing the evidence base against individual patient needs and preferences.

For further reading and ongoing updates in this rapidly evolving field, clinicians can consult the following resources: